MetaVia Inc. Files 8-K: Material Agreement, Equity Sales

Ticker: MTVA · Form: 8-K · Filed: May 14, 2025 · CIK: 1638287

Metavia INC. 8-K Filing Summary
FieldDetail
CompanyMetavia INC. (MTVA)
Form Type8-K
Filed DateMay 14, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: material-agreement, equity-sale, corporate-update

TL;DR

MetaVia (formerly NeuroBo/Gemphire) signed a big deal & sold some stock on 5/8.

AI Summary

On May 8, 2025, MetaVia Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and other events. MetaVia Inc. was formerly known as NeuroBo Pharmaceuticals, Inc. and Gemphire Therapeutics Inc.

Why It Matters

This filing indicates significant corporate activity for MetaVia Inc., including a new material agreement and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks if not managed properly.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by MetaVia Inc. on May 8, 2025?

The filing states that MetaVia Inc. entered into a material definitive agreement on May 8, 2025, but the specific details of this agreement are not provided in this document.

What were the terms of the unregistered sales of equity securities by MetaVia Inc.?

The filing reports on unregistered sales of equity securities by MetaVia Inc., but the specific terms, amounts, or recipients of these sales are not detailed in this 8-K filing.

When did MetaVia Inc. change its name from NeuroBo Pharmaceuticals, Inc.?

MetaVia Inc. changed its name from NeuroBo Pharmaceuticals, Inc. on December 31, 2019.

What is MetaVia Inc.'s Standard Industrial Classification (SIC) code?

MetaVia Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

What is the business address of MetaVia Inc.?

MetaVia Inc.'s business address is 545 Concord Avenue, Suite 210, Cambridge, MA 02138.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 14, 2025 regarding MetaVia Inc. (MTVA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing